SCHEMBL12199729

SCHEMBL12199729

O=C1NC(=O)C2(CCc3ccccc3CC2)N1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
CRBN Q96SW2 7/20 0.50
AKR1B1 P15121 1/20 0.50
DDB1 Q16531 2/20 0.44
PDE7A Q13946 1/20 0.42
CACNA1F O60840 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
SCN1A P35498 1/20 0.41
SCN4A P35499 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
CACNA1D Q01668 1/20 0.41
KCNH2 Q12809 1/20 0.41
CACNA1S Q13698 1/20 0.41
CACNA1C Q13936 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrantoin SCHEMBL79518 0.93 TSHR (0.54) TSHRTDP1CRBNAKR1B1DDB1
Tetrantoin SCHEMBL29582305 0.93 TSHR (0.54) TSHRTDP1CRBNAKR1B1DDB1
SCHEMBL409009 0.80 TSHR (0.47) TSHRTDP1CRBNAKR1B1DDB1
SCHEMBL16659357 0.80 TSHR (0.42) TSHRTDP1CRBNAKR1B1PDE7A
SCHEMBL12199728 0.80 TSHR (0.42) TSHRTDP1CRBNAKR1B1MAPT
SCHEMBL30667158 0.78 TSHR (0.50) TSHRTDP1CRBNAKR1B1DDB1
SCHEMBL7923379 0.77 PDE7A (0.44) TSHRTDP1CRBNAKR1B1DDB1
SCHEMBL573359 0.77 CRBN (0.41) TSHRTDP1CRBNAKR1B1DDB1
SCHEMBL16659358 0.76 ALDH1A1 (0.53) TSHRTDP1CRBNDDB1PDE7A
SCHEMBL8775591 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296750-B2 Spirolactam CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-03-29 US disclosed
US-20150111914-A1 SPIROLACTAM CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2015-04-23 US disclosed
US-20110245240-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245240-A1 CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, QRFPR TSHR 325/4885TDP1 3318/4885CRBN 3154/4885
US-20150111914-A1 SPIROLACTAM CGRP RECEPTOR ANTAGONISTS CALCRL, CALCR, TACR1 TSHR 762/4885TDP1 2415/4885CRBN 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.